FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
Why now
Thesis: Coverage decision could reprice cancer-screening diagnostics
Catalyst to watch: FDA adviser vote and Medicare ruling
Main risk: Study failed to prove later-stage detection
Why it matters
Medicare coverage for Grail's Galleri could expand multi-cancer screening revenue, but a failed study undercuts the clinical evidence.
Details
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Related assets & topics
HealthcareSources
- marketwatch · 2026-09-23 12:39 UTC